

## Namzaric® (memantine/donepezil) - First-time generic

- On January 23, 2025, <u>Amneal launched</u> an <u>AB-rated</u> generic version of AbbVie's <u>Namzaric</u> (memantine/donepezil) 14 mg/10 mg and 28 mg/10 mg extended-release capsules.
  - Amneal has been granted 180 days of generic exclusivity for its generic Namzaric.
  - ANI Pharmaceuticals received FDA approval of an <u>AB-rated</u> generic version of Namzaric 21 mg/10 mg extended-release capsules on December 15, 2023. Launch is pending.
  - Namzaric is also available as a 7 mg/10 mg extended-release capsule.
- Namzaric is approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily.
- According to IQVIA<sup>®</sup>, Namzaric had annual U.S. sales of \$88 million as of November 2024.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.